CLCM
SRPT icon

Crawford Lake Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Crawford Lake Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20,511
Closed -$2.65M – 72
2019
Q4 		$2.65M Buy
+20,511
New +$2.07M 0.4% 48
2018
Q3 		– Sell
-46,415
Closed -$6.13M – 103
2018
Q2 		$6.13M Buy
+46,415
New +$4.38M 1.07% 32

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Crawford Lake Capital Management's SRPT Position: Q1 2020 in Review

Crawford Lake Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2020, closing a stake of 20,511 shares — an estimated $2.65M sold.

Crawford Lake Capital Management first reported a position in SRPT in Q2 2018 and held it in 2 quarters. The position peaked at $6.13M in Q2 2018. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

  • Crawford Lake Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Crawford Lake Capital Management sold 20,511 Sarepta Therapeutics shares in Q1 2020, an estimated $2.65M.
  • Crawford Lake Capital Management first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 2 quarters.
  • Crawford Lake Capital Management's Sarepta Therapeutics position peaked at $6.13M in Q2 2018.
  • 366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on Crawford Lake Capital Management's 13F filing for Q1 2020, filed 15 May 2020.